Please note that the ANZCTR will be unattended from Friday the 17th of July to Monday the 20th of July 2020 inclusive. Thank you and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
A Gene Transfer Study for Hemophilia A
Scientific title
Gene Transfer, Dose-Finding Safety, Tolerability, and Efficacy Study of SPK-8011 [a Recombinant Adeno-Associated Viral Vector With Human Factor VIII Gene] in Individuals With Hemophilia A
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hemophilia A 0 0
Condition category
Condition code
Blood 0 0 0 0
Clotting disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Study type
Description of intervention(s) / exposure
Other interventions - SPK-8011

Experimental: SPK-8011 - All participants who meet the eligibility criteria will receive an outpatient single intravenous (i.v.) administration of SPK-8011.

Other interventions: SPK-8011
A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Number of study-related adverse events, including clinically significant abnormal laboratory values - adverse events
Timepoint [1] 0 0
52 weeks
Primary outcome [2] 0 0
Changes from baseline in FVIII activity levels after a single outpatient administration of SPK-8011 - changes in FVIII activity levels
Timepoint [2] 0 0
52 weeks
Secondary outcome [1] 0 0
Kinetic assessment of SPK-8011 including shedding of vector DNA in bodily fluids - vector shedding
Timepoint [1] 0 0
52 weeks
Secondary outcome [2] 0 0
Number of participants requiring a course of steroid therapy for the elevations in liver enzymes - number of participants requiring steroids
Timepoint [2] 0 0
52 weeks

Key inclusion criteria
- Males age18 years or older

- Confirmed diagnosis of hemophilia A as evidenced by their medical history with plasma
FVIII activity levels = 2% of normal

- Have received >150 exposure days (EDs) to FVIII concentrates or cryoprecipitate

- Have experienced >10 bleeding events over the previous 12 months only if receiving
on-demand therapy and having FVIII baseline level 1-2% of normal

- Have no prior history of allergic reaction to any FVIII product

- Have no measurable inhibitor against Factor VIII as assessed by the central laboratory
and have no prior history of inhibitors to FVIII protein

- Agree to use reliable barrier contraception
Minimum age
18 Years
Maximum age
No limit
Can healthy volunteers participate?
Key exclusion criteria
- Evidence of active hepatitis B or C

- Currently on antiviral therapy for hepatitis B or C

- Have significant underlying liver disease

- Have serological evidence* of HIV-1 or HIV-2 with CD4 counts =200/mm3 (* participants
who are HIV+ and stable with CD4 count >200/mm3 and undetectable viral load are
eligible to enroll)

- Have detectable antibodies reactive with AAV-Spark200 capsid

- Participated in a gene transfer trial within the last 52 weeks or in a clinical trial
with an investigational product within the last 12 weeks

Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 1/Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Prince Alfred Hosptial - Camperdown
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Country [2] 0 0
United States of America
State/province [2] 0 0
Country [3] 0 0
United States of America
State/province [3] 0 0
Country [4] 0 0
United States of America
State/province [4] 0 0
New York
Country [5] 0 0
United States of America
State/province [5] 0 0
North Carolina
Country [6] 0 0
United States of America
State/province [6] 0 0
Country [7] 0 0
United States of America
State/province [7] 0 0
Country [8] 0 0
State/province [8] 0 0

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Spark Therapeutics

Ethics approval
Ethics application status

Brief summary
This clinical research study is being conducted by Spark Therapeutics, Inc. to determine the
safety and efficacy of the factor VIII gene transfer treatment with SPK-8011 in individuals
with hemophilia A.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Lindsey George, MD
Address 0 0
Children's Hospital of Philadelphia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Clinical Director
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see